Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents

Expert Opinion on Investigational Drugs

Volumn 23, Issue 5, 2014, Pages 661-673

  Sharlow, Elizabeth R ^a   Wipf, Peter ^b   McQueeney, Kelley E ^a   Bakan, Ahmet ^c   Lazo, John S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody therapy; Cancer chemotherapy; Enzyme inhibitor; Oncogenic phosphatase; Thienopyridone

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; LIGAND; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PTP4A3 PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG; NEW DRUG; PTP4A3 PROTEIN, HUMAN; TUMOR PROTEIN;

BIOLOGY; DRUG DESIGN; DRUG IDENTIFICATION; ENZYME STRUCTURE; HUMAN; IN VIVO STUDY; MOLECULAR MODEL; MOLECULE; NEOPLASM; NONHUMAN; PROTEIN FUNCTION; REVIEW; VALIDATION PROCESS; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES;

EID: 84898472215     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.892579     Document Type: Review

References (71)

1. Sacco F, Perfetto L, Castagnoli L, Cesareni G. The human phosphatase interactome: An intricate family portrait. FEBS Lett 2012;586:2732-9
2. Jin J, Pawson T. Modular evolution of phosphorylation-based signalling systems. Philos Trans R Soc Lond B Biol Sci 2012;367:2540-55
3. Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphatases in the human genome. Cell 2004;117:699-711
4. Barford D. Protein phosphatase. Curr Opin Struct Biol 1995;5:728-34
5. McConnell JL, Wadzinski BE. Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol 2009;75:1249-61
6. Tonks NK. Protein tyrosine phosphatases-from housekeeping enzymes to master regulators of signal transduction. FEBS J 2013;280:346-78
7. Brautigan DL. Protein Ser/Thr phosphatases-The ugly ducklings of cell signalling. FEBS J 2013;280:324-245
8. Saha S, Bardelli A, Buckhaults P, et al. A phosphatase associated with metastasis of colorectal cancer. Science 2001;294:1343-6
9. Bardelli A SS, Sager JA, Romans KE, et al. PRL-3 expression in metastatic cancers. Clin Cancer Res 2003;9:5607-15
10. Guzin'ska-Ustymowicz K, Pryczynicz A. PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis. Anticancer Agents Med Chem 2011;11:99-108
11. Liang F, Liang J, Wang WQ, et al. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 2007;282:5413-19
12. Stephens BJ, Han H, Gokhale V, Von Hoff DD. PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther 2005;4:1653-61
13. Peng L, Xing X, Li W, et al., PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling. Mol Cancer 2009;8:110
14. Zhou J, Bi C, Chng WJ, et al. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS One 2011;6:e19798
15. Park JE, Yuen HF, Zhou JB, et al. Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia. EMBO Mol Med 2012;5:1351-66
16. Xu J, Cao S, Wang L, et al. VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C. PLoS One 2011;6:e27165
17. Rouleau C, Roy A, St Martin T, et al. Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: Expression and function. Mol Cancer Ther 2006;5:219-29
18. Matsukawa Y, Semba S, Kato H, et al. Constitutive suppression of PRL-3 inhibits invasion and proliferation of gastric cancer cell in vitro and in vivo. Pathobiol 2010;77:155-62
19. Polato F, Codegoni A, Fruscio R, et al. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res 2005;11:6835-9
20. Daouti S, Li WH, Qian H, et al. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res 2008;68:1162-9
21. Qian F, Li YP, Sheng X, et al. PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo. Mol Med 2007;13:151-9
22. KatoH, Semba S, Miskad UA, et al. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: A predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 2004;10:7318-28
23. Stephens B, Han H, Hostetter G, et al. Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol Cancer Ther 2008;7:202-10
24. Li Z, Zhan W, Wang Z, et al. Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis. Biochem Biophy Res Comm 2006;348:229-37
25. Zimmerman MW, Homanics GE, Lazo JS. Targeted deletion of the metastasis-Associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer. PLoS One 2013;8:e58300
26. Zimmerman MW, McQueeney KE, Isenberg JS, et al. PTP4A3 phosphatase promotes VEGF signaling and enables endothelial cell motility. J Biol Chem 2014. [Epub ahead of print]
27. Maltzman T, Whittington J, Driggers L, et al. AOM-induced mouse colon tumors do not express full-length APC protein. Carcinogenesis 1997;18:2435-9
28. Diamond RH, Cressman DE, Laz TM, et al. PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol Cell Biol 1994;14:3752-62
29. Sun JP, Wang WQ, Yang H, et al. Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion. Biochemistry 2005;44:12009-21
30. Kim K-A, Song J-S, Jee J, et al. Structure of human PRL-3, the phosphatase associated with cancer metastasis. FEBS Lett 2004;565:181-7
31. Kozlov G, Cheng J, Ziomek E, et al. Structural insights into molecular function of the metastasis-Associated phosphatase PRL-3. J Biol Chem 2004;279:11882-9
32. Sun JP, Luo Y, Yu X, et al. Phosphatase activity, trimerization, and the C-Terminal polybasic region are all required for PRL1-mediated cell growth and migration. J Biol Chem 2007;282:29043-51
33. Bessette DC, Qiu D, Pallen CJ. PRL PTPs: Mediators and markers of cancer progression. Cancer Metastasis Rev 2008;27:231-52
34. Si X, Zeng Q, Ng CH, et al. Interaction of farnesylated PRL-2, a protein-Tyrosine phosphatase, with the beta-subunit of geranylgeranyltransferase II. J Biol Chem 2007;276:32875-82
35. Zeng Q, Si X, Horstmann H, et al. Prenylation-dependent association of protein-Tyrosine phosphatases PRL-1,-2, and-3 with the plasma membrane and the early endosome. J Biol Chem 2000;275:21444-52
36. McParland V, Varsano G, Li X, et al. The metastasis-promoting phosphatase PRL-3 shows activity toward phosphoinositides. Biochemistry 2011;50:7579-90
37. Forte E, Orsatti L, Talamo F, et al. Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3. Biochim Biophys Acta 2008;1783:334-44
38. Peng L, Jin G, Wang L, et al. Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3. Biochem Biophys Res Commun. 2006;342:179-83
39. Tian W, Qu L, Meng L, et al. Phosphatase of regenerating liver-3 directly interacts with integrin beta1 and regulates its phosphorylation at tyrosine 783. BMC Biochem 2012;13:22
40. Semba S, Mizuuchi E, Yokozaki H. Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma. Cancer Sci 2010;101:2254-61
41. Mizuuchi E, Semba S, Kodama Y, Yokozaki H. Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression. Int J Cancer 2009;124:1802-10
42. Zheng P, Liu YX, Chen L, et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 2010;9:4897-905
43. Ishii T, Funato Y, Miki H. Thioredoxin-related protein 32 (TRP32) specifically reduces oxidized phosphatase of regenerating liver (PRL). J Biol Chem 2013;288:7263-70
44. Lian S, Meng L, Liu C, et al. PRL-3 activates NF-kappaB signaling pathway by interacting with RAP1. Biochem Biophy Res Comm 2013;430:196-201
45. Orsatti L, Forte E, Tomei L, et al. 2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: A successful approach for the identification of kinase/phosphatase targets. Electrophoresis 2009;30:2469-76
46. Fiordalisi JJ, Keller PJ, Cox AD. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res 2006;66:3153-61
47. Al-Aidaroos AQO, Yuen HF, Guo K, et al. Metastasis-Associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest 2013;123:3459-71
48. Choi MS, Min SH, Jung H, et al. The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability. Biochem Biophys Res Commun 2011;406:305-9
49. Choi SK, Oh HM, Lee SK, et al. Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-3). Nat Prod Res 2006;20:341-6
50. Chou LC, Chen CT, Lee JC, et al. Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent. J Med Chem 2010;53:1616-26
51. Min G, Lee SK, Kim HN, et al. Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells. Bioorg Med Chem Lett 2013;23:3769-74
52. Park H, Jung SK, Jeong DG, et al. Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening. Bioorg Med Chem Lett 2008;18:2250-5
53. Pathak MK, Dhawan D, Lindner DJ, et al. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther 2002;1:1255-64
54. Lazo JS, Wipf P. Phosphatases as targets for cancer treatment. Curr Opin Invest Drugs 2009;10:1297-304
55. Vintonyak VV, Waldmann H, Rauh D. Using small molecules to target protein phosphatases. Bioorg Med Chem 2011;19:2145-55
56. Moon MK, Han Y-M, Lee Y-J, et al. Inhibitory activities of anthraquinones from rubia akane on phosphatase regenerating liver-3. Arch Pharmacal Res 2010;33:1747-51
57. Han YM, Lee SK, Jeong DG, et al. Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity. Bioorg Med Chem Lett 2012;22:323-6
58. Lazo JS, Wipf P. Is Cdc25 a druggable target? Anti-cancer Agents Med Chem 2008;8:837-42
59. Ahn JH, Kim SJ, Park WS, et al. Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorg Med Chem Lett 2006;16:2996-9
60. Xia X, Yang J, Li F, et al. Image-based chemical screening identifies drug efflux inhibitors in lung cancer cells. Cancer Res 2010;70:7723-33
61. Mendgen T, Steuer C, Klein CD. Privileged scaffolds or promiscuous binders: A comparative study on rhodanines and related heterocycles in medicinal chemistry. J Med Chem 2012;55:743-53
62. Guo K, Tang JP, Tan CP, et al. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol Ther 2008;7:750-7
63. Guo K, Li J, Tang JP, et al. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med 2011;3:99ra85
64. Guo K, Tang JP, Jie L, et al. Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice. Oncotarget 2012;3(2):158-71
65. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779-815
66. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera-A visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605-12
67. Bakan A, Nevins N, Lakdawala AS, Bahar I. Druggability assessment of allosteric proteins by dynamics simulations in the presence of probe molecules. J Chem Ther Comput 2012;8:2435-47
68. Nelson MT, Humphrey W, Gursoy A, et al. NAMD: A parallel, object-oriented molecular dynamics program. Intl J High Perf Comp Applications 1996;10:251-68
69. Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph 1996;14:33-8
70. Molina G, Vogt A, Bakan A, et al. An allosteric inhibitor of Dusp6, identified by a transgenic zebrafish chemical screen, expands cardiac progenitors and heart size. Nat Cell Biol 2009;5:680-7
71. Fiordalisi JJ, Dewar BJ, Graves LM, et al. Src-mediated phosphorylation of the tryrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion. PLoS One 2013;8:e64309